Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BHV-0223 in ALS
NCT03520517Phase 1Completed
- Sponsor
- Biohaven Ltd.
- Start
- Feb 2018
- Primary completion
- Oct 2018
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rivastigmine in amyotrophic lateral sclerosis (ALS), sponsored by Biohaven Ltd. Primary endpoint: Incidence of Treatment Emergent Adverse Events at 8 weeks. Started Feb 2018; status: completed.
02
Drugs
rivastigmine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03520517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520517.